Intrapulmonary BCG cell wall vaccination in mice.

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Mycobacterium bovis bacille Calmette-Guérin (BCG) is used as a vaccine against tuberculosis.
• Understanding the most effective routes for BCG immunization is crucial for optimizing tuberculosis prevention strategies.

Purpose of the Study:

• To compare the efficacy of intratracheal versus systemic immunization with BCG cell wall vaccine in conferring protection against Mycobacterium bovis BCG infection.
• To evaluate the impact of different immunization routes on mycobacterial load in mouse lungs and spleens.

Main Methods:

• Two inbred mouse strains (Balb/c and C3H/He) were infected with varying doses of Mycobacterium bovis BCG via intravenous or intratracheal routes.
• Mice were immunized with BCG cell wall vaccine intratracheally, intravenously, or subcutaneously, then challenged intratracheally with live BCG.
• Mycobacterial multiplication in spleen and lung, along with weight changes, were measured to assess infection magnitude and immune response.

Main Results:

• Intratracheal infection led to significantly higher mycobacterial lung counts compared to intravenous infection in both mouse strains.
• Balb/c mice were more susceptible to BCG infection than C3H/He mice.
• Intratracheal immunization with BCG cell wall vaccine significantly reduced lung mycobacterial counts upon challenge, unlike intravenous or subcutaneous immunization.

Conclusions:

• Intratracheal immunization with BCG cell wall vaccine induces more effective intrapulmonary immunity against Mycobacterium bovis BCG than systemic immunization routes.
• The route of immunization plays a critical role in the development of localized mucosal immunity against mycobacterial lung infections.